Darzalex (daratumumab): Insurance Coverage and Denials
A plain-language guide to anti-CD38 monoclonal antibody coverage, why insurers deny it, and where to get cancer-specific help.
Darzalex is an immunotherapy and the first FDA-approved monoclonal antibody that targets the CD38 protein found on the surface of myeloma cells. By binding CD38, it triggers several immune-driven mechanisms that help destroy cancer cells. The FDA has approved Darzalex for multiple myeloma, both alone in certain previously treated patients and in combination with other agents such as bortezomib, lenalidomide, and dexamethasone across different lines of therapy.
Insurers commonly require prior authorization and often verify diagnosis, prior treatments, and the specific combination regimen requested. Because Darzalex is given as an infusion or injection, denials and delays can also involve site-of-care policies or requests for additional documentation.
If coverage is denied, you generally have the right to an internal appeal and then an independent external review under federal protections such as 45 CFR 147.136. For cancer-specific support, contact the PAN Foundation, Patient Advocate Foundation, Triage Cancer, CancerCare, or Janssen's Darzalex copay and patient-assistance programs.
Where to get cancer-specific help
A note on scope. Apellica focuses on appeals for non-oncology insurance denials and does not handle cancer-related appeal cases. Cancer coverage involves complex, fast-moving clinical and financial questions, and patients are best served by organizations built specifically for oncology. If you are facing a cancer drug denial, please reach out to the specialized groups listed on this page, including the PAN Foundation, the Patient Advocate Foundation, Triage Cancer, and CancerCare, along with the manufacturer's own copay or patient-assistance program. They offer free, expert, cancer-focused support, and they can help you understand your options and protect your access to treatment. ---
- PAN Foundation Copay and financial assistance funds for specific diagnoses.
- Patient Advocate Foundation Case managers who help with insurance denials and appeals for serious illness.
- Triage Cancer Free education and resources on cancer-related insurance and appeals.
- CancerCare Professional support services and financial assistance.
Oncology clinics and manufacturers
Apellica partners with infusion centers, oncology practices, and pharmaceutical manufacturers on denial recovery and patient access at scale. If you are exploring a partnership, we would like to talk.
Partner with usFrequently asked questions
- Why do insurers deny Darzalex?
- Line-of-therapy requirements; Site-of-care restrictions; Prior authorization criteria.
- Can I appeal a Darzalex denial?
- Yes. You generally have the right to an internal appeal and then an independent external review under federal rules such as 45 CFR 147.136. For cancer-specific help, the organizations listed on this page specialize in oncology coverage.